VCJ Fact Sheet for Nick Galakatos
Born: Athens, Greece
Education: Ph.D. in Organic Chemistry from M.I.T.; Post-doctoral work in molecular biology at Harvard Medical School.
Career Path: Dr. Nick Galakatos is a General Partner at MPM Capital. He joined MPM in 2000 from Millennium Pharmaceuticals, where he was Vice President, New Businesses and led the building of spinout companies in the biotherapeutics, diagnostics and drug delivery fields. Prior to his work at Millennium, Dr. Galakatos was an Associate at Venrock Associates where he focused on early-stage life science investments. Dr. Galakatos joined Venrock from Ciba-Geigy’s Pharmaceuticals Division where he was Head, Molecular Biology Research and Venture Manager in Corporate Planning as a liaison to Accel Partners. Galakatos is a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals.
Venture Focus: Life sciences
Investments: Affymax; Caliper Technologies; Critical Therapeutics; IDUN Pharmaceuticals; Sention; Syrrx Symyx, Transform Pharmacueticals.
Misc. affiliations: Harvard Medical School Advisory Council for Biological Chemistry and Molecular Pharmacology.
Greatest Accomplishment: Founding investor in Caliper, founder of Millennium spinouts.
Biggest Mistake: Did not invest more in Millennium in the early days.
If you weren’t a VC, you’d be a? Restaurateur
Pet Peeve: Waiting for things to happen by themselves.
Did You Know? Was a Chemistry Professor at Reed College.
Are we missing something?